Investor & Corporate Presentations Date Title Corporate Presentation - August 2022 8/12/22 Topline Results for Phase 2 Clinical Trial of OTX-DED for the Short-term Treatment of Dry Eye Disease Presentation 12/6/21 Topline Data: Dextenza For the Treatment of Allergic Conjunctivitis 4/28/20
Topline Results for Phase 2 Clinical Trial of OTX-DED for the Short-term Treatment of Dry Eye Disease Presentation 12/6/21
